Geode Capital Management’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-440,349
| Closed | -$61.7K | – | 4658 |
|
|
2024
Q1 | $61.7K | Hold |
440,349
| – | – | ﹤0.01% | 4276 |
|
|
2023
Q4 | $64.1K | Buy |
440,349
+127,123
| +41% | +$19.7K | ﹤0.01% | 4291 |
|
|
2023
Q3 | $54.9K | Sell |
313,226
-4,323
| -1% | -$5.37K | ﹤0.01% | 4399 |
|
|
2023
Q2 | $991K | Buy |
317,549
+121,309
| +62% | +$361K | ﹤0.01% | 3361 |
|
|
2023
Q1 | $502K | Buy |
196,240
+21,316
| +12% | +$44K | ﹤0.01% | 3647 |
|
|
2022
Q4 | $260K | Buy |
174,924
+9,273
| +6% | +$15K | ﹤0.01% | 3953 |
|
|
2022
Q3 | $288K | Buy |
165,651
+86,287
| +109% | +$122K | ﹤0.01% | 4009 |
|
|
2022
Q2 | $103K | Hold |
79,364
| – | – | ﹤0.01% | 4580 |
|
|
2022
Q1 | $188K | Buy |
79,364
+4,221
| +6% | +$11K | ﹤0.01% | 4411 |
|
|
2021
Q4 | $344K | Sell |
75,143
-207
| -0.3% | -$684 | ﹤0.01% | 4229 |
|
|
2021
Q3 | $610K | Buy |
75,350
+4,094
| +6% | +$35.1K | ﹤0.01% | 3937 |
|
|
2021
Q2 | $700K | Sell |
71,256
-45,010
| -39% | -$366K | ﹤0.01% | 3778 |
|
|
2021
Q1 | $1.02M | Buy |
116,266
+2,558
| +2% | +$28.1K | ﹤0.01% | 3553 |
|
|
2020
Q4 | $1.16M | Buy |
113,708
+12,110
| +12% | +$132K | ﹤0.01% | 3322 |
|
|
2020
Q3 | $918K | Buy |
101,598
+7,413
| +8% | +$58.7K | ﹤0.01% | 3245 |
|
|
2020
Q2 | $672K | Buy |
94,185
+44,968
| +91% | +$477K | ﹤0.01% | 3272 |
|
|
2020
Q1 | $467K | Buy |
49,217
+11,843
| +32% | +$153K | ﹤0.01% | 3294 |
|
|
2019
Q4 | $491K | Buy |
+37,374
| New | +$456K | ﹤0.01% | 3510 |
|
Other funds holding GRTX
Geode Capital Management's GRTX Position: Q2 2024 in Review
Geode Capital Management sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q2 2024, closing a stake of 440,349 shares — an estimated $61.7K sold.
Geode Capital Management first reported a position in GRTX in Q4 2019 and held it in 18 quarters. The position peaked at $1.16M in Q4 2020. 1 fund tracked by Wall St. Rank holds GRTX as of Q2 2024.
- Geode Capital Management reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Geode Capital Management sold 440,349 Galera Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $61.7K.
- Geode Capital Management first reported a position in Galera Therapeutics, Inc. Common Stock in Q4 2019 and held it in 18 quarters.
- Geode Capital Management's Galera Therapeutics, Inc. Common Stock position peaked at $1.16M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q2 2024.
Based on Geode Capital Management's 13F filing for Q2 2024, filed 9 Aug 2024.